Changeflow GovPing Healthcare & Life Sciences Recurium IP Holdings WEE1 Inhibitor Patent
Routine Rule Added Final

Recurium IP Holdings WEE1 Inhibitor Patent

Favicon for changeflow.com USPTO Patent Grants - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The USPTO granted Patent US12606567B2 to Recurium IP Holdings, LLC on April 21, 2026, covering salts and forms of WEE1 inhibitor Compound A, including adipate salt Form A. The patent discloses pharmaceutical applications for treating diseases characterized by excessive cellular proliferation, including breast cancer. The patent contains 23 claims under CPC classifications C07D 487/04 and C07B 2200/13.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The USPTO issued Patent US12606567B2 granting Recurium IP Holdings, LLC exclusive rights to salt forms (including adipate salt Form A) and freebase forms of WEE1 inhibitor Compound A. The patent protects pharmaceutical compositions and methods of treating conditions characterized by excessive cellular proliferation, including breast cancer.

For pharmaceutical companies developing WEE1 inhibitors or related oncology therapeutics, this patent may represent a blocking patent in the WEE1 inhibitor space. Competitors should evaluate freedom-to-operate positions and consider potential licensing discussions. The patent does not impose compliance obligations but creates enforceable IP rights effective from the April 21, 2026 grant date.

Archived snapshot

Apr 21, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Salts and forms of a WEE1 inhibitor

Grant US12606567B2 Kind: B2 Apr 21, 2026

Assignee

Recurium IP Holdings, LLC

Inventors

Chad Daniel Hopkins, Peter Qinhua Huang, Kevin Duane Bunker

Abstract

The salt, such as adipate salt Form A, and freebase forms of Compound A are WEE1 inhibitors. Such salts and/or forms and freebase forms, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.

CPC Classifications

C07D 487/04 C07B 2200/13

Filing Date

2021-07-08

Application No.

18004628

Claims

23

View original document →

Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 21st, 2026
Instrument
Rule
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies Manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent grant Drug compound protection Oncology therapeutics
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!